Table 1.
Characteristics of studies included in the InterLymph NHL Subtypes Project*
| Controls | Cases | |
|---|---|---|
| No. (%) | No. (%) | |
| Total | 23096 | 152 |
| Study | ||
| New South Wales | 694 (3.0) | 5 (3.3) |
| Mayo Clinic | 1314 (5.7) | 1 (0.7) |
| British Columbia | 845 (3.7) | 6 (3.9) |
| Nebraska (newer) | 533 (2.3) | 1 (0.7) |
| United Kingdom | 1139 (4.9) | 0 (0.0) |
| NCI-SEER | 1055 (4.6) | 0 (0.0) |
| UCSF1 | 2402 (10.4) | 12 (7.9) |
| EpiLymph | 2460 (10.7) | 46 (30.3) |
| Yale | 717 (3.1) | 3 (2.0) |
| SCALE | 3187 (13.8) | 15 (9.9) |
| Los Angeles | 375 (1.6) | 16 (10.5) |
| Italy multicenter | 1771 (7.7) | 12 (7.9) |
| Italy (Aviano-Milan) | 1157 (5.0) | 10 (6.6) |
| Italy (Aviano-Naples) | 504 (2.2) | 0 (0.0) |
| Iowa/Minnesota | 1245 (5.4) | 6 (3.9) |
| Kansas | 948 (4.1) | 1 (0.7) |
| Nebraska (older) | 1432 (6.2) | 3 (2.0) |
| Engela | 722 (3.1) | 8 (5.3) |
| UCSF2 | 457 (2.0) | 7 (4.6) |
| University of Rochester | 139 (0.6) | 0 (0.0) |
| Region | ||
| North America | 11462 (49.6) | 56 (36.8) |
| Northern Europe | 6542 (28.3) | 59 (38.8) |
| Southern Europe | 4398 (19.0) | 32 (21.1) |
| Australia | 694 (3.0) | 5 (3.3) |
| Design | ||
| Population based | 17846 (77.3) | 104 (68.4) |
| Hospital based | 5250 (22.7) | 48 (31.6) |
| Total | 23096 (100.0) | 152 (100.0) |
| Age | ||
| <30 | 1360 (5.9) | 38 (25.0) |
| 30–39 | 2180 (9.4) | 36 (23.7) |
| 40–49 | 3159 (13.7) | 16 (10.5) |
| 50–59 | 4992 (21.6) | 30 (19.7) |
| 60–69 | 6380 (27.6) | 24 (15.8) |
| 70–79 | 4136 (17.9) | 6 (3.9) |
| ≥80 | 873 (3.8) | 2 (1.3) |
| Missing | 16 (0.1) | 0 (0.0) |
| Sex | ||
| Male | 13495 (58.4) | 92 (60.5) |
| Female | 9601 (41.6) | 60 (39.5) |
| Race/ethnicity | ||
| White, non-Hispanic | 21576 (93.4) | 132 (86.8) |
| Black | 351 (1.5) | 1 (0.7) |
| Asian | 321 (1.4) | 7 (4.6) |
| Hispanic | 360 (1.6) | 6 (3.9) |
| Other/unknown/missing | 488 (2.1) | 6 (3.9) |
| SES | ||
| Low | 9335 (40.4) | 51 (33.6) |
| Medium | 6709 (29.0) | 53 (34.9) |
| High | 6642 (28.8) | 48 (31.6) |
| Other/missing | 410 (1.8) | 0 (0.0) |
| NHL classification scheme | ||
| World Health Organization | 13766 (59.6) | 92 (60.5) |
| Working Formulation | 9330 (40.4) | 60 (39.5) |
| ALL cell type | ||
| B cell | 0 (0.0) | 55 (36.2) |
| T cell | 0 (0.0) | 48 (31.6) |
| NOS | 0 (0.0) | 49 (32.2) |
| Missing | 23 096 (100.0) | 0 (0.0) |
* ALL = acute lymphoblastic leukemia/lymphoma; NCI-SEER = National Cancer Institute-Surveillance, Epidemiology, and End Results; NHL = non-Hodgkin lymphoma; NOS = not otherwise specified; SCALE = Scandinavian Lymphoma Etiology Study; SES = socioeconomic status; UCSF = University of California San Francisco.